Recent reports of the SOAR (Study of Androgen Replacement) trial demonstrated that oral testosterone therapy achieved recommend range of normal therapeutic testosterone levels in 88% of men studied.  
Currently there are no FDA approved oral testosterone products because testosterone absorbed in the stomach would be converted to an inactive form by the liver.  This is called the first pass effect.  LPCN-1021 employs a novel lipid-like oral delivery technology that allows predictable effective dosing.  There are many testoterone products available now but this drug would be unique because it is a pill.